Hepatic adenoma masquerading as a hepatocellular carcinoma in a patient with a Fontan procedure on the oral contraceptive pill

Yao, J.; Sood, Siddharth; Lokan, Julie; Murugasu, Anand; Grigg, Leeanne; Zentner, Dominica

doi:10.1111/imj.15267

Cited by 3 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…14 In one systematic review, 9 out of 10 nodules ultimately diagnosed as HCC were visible on ultrasound. 15 Until better data becomes available, screening with ultrasound every 6 months is reasonable.…”

Section: Discussionmentioning

confidence: 99%

A meta-analysis of cumulative incidence of hepatocellular carcinoma after the Fontan operation

Hansen,

Gilroy,

Lindsay

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Hepatic complications are increasingly recognized after the Fontan operation. The development of hepatocellular carcinoma (HCC) is associated with high mortality when diagnosed, but its incidence and risk factors are poorly understood. We conducted a systematic review and meta-analysis of the cumulative incidence of HCC after Fontan and associated risk factors. Methods We searched PubMed, CINAHL, and MEDLINE databases for articles reporting the cumulative incidence of HCC after Fontan operation on March 21, 2023. A single-arm random effects meta-analysis was conducted to assess cumulative incidence at 10-, 20-, and 30-years after Fontan. Meta-analysis of the difference of the medians was used to assess the influence of risk factors on the development of HCC. Results Four studies including a total of 1,320 patients reported cumulative incidence. The cumulative incidence of HCC at 10-, 20-, and 30-years after Fontan was 0% (95% CI 0.00-0.01), 2% (0.01–0.06), and 7% (0.03–0.17) respectively. Seven studies including 6,250 patients reported overall incidence of HCC and associated risk factors. At a median 18.4 (IQR 11.9–24.9) years of follow-up, incidence of HCC was 2% (0.01–0.04). Only use of anticoagulation was associated with a lower risk of HCC (RR 0.3, 95% CI 0.1–0.88). Discussion By 30 years after Fontan, cumulative incidence of HCC is high (7%). Risk of HCC development prior to 10-years post-Fontan is low (0%) and HCC screening can be safely deferred in this population. Screening with ultrasound every 6 months starting 20-years post-Fontan is reasonable, however, further research regarding timing, cost-effectiveness, additional risk factors associated with HCC risk, and different screening modalities is required.

show abstract

Section: Discussionmentioning

confidence: 99%

A meta-analysis of cumulative incidence of hepatocellular carcinoma after the Fontan operation

Hansen,

Gilroy,

Lindsay

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

A Meta-Analysis of Cumulative Incidence of Hepatocellular Carcinoma After the Fontan Operation

Hansen,

Gilroy,

Lindsay

et al. 2024

Dig Dis Sci

View full text Add to dashboard Cite

BackgroundHepatic complications are increasingly recognized after the Fontan operation. The development of hepatocellular carcinoma (HCC) is associated with high mortality when diagnosed, but its incidence and risk factors are poorly understood. We conducted a systematic review and meta-analysis of the cumulative incidence of HCC after Fontan and associated risk factors. MethodsWe searched PubMed, CINAHL, and MEDLINE databases for articles reporting the cumulative incidence of HCC after Fontan operation on March 21, 2023. A single-arm random effects meta-analysis was conducted to assess cumulative incidence at 10-, 20-, and 30-years after Fontan. Meta-analysis of the difference of the medians was used to assess the in uence of risk factors on the development of HCC. ResultsFour studies including a total of 1,320 patients reported cumulative incidence. The cumulative incidence of HCC at 10-, 20-, and 30-years after Fontan was 0% (95% CI 0.00-0.01), 2% (0.01-0.06), and 7% (0.03-0.17) respectively. Seven studies including 6,250 patients reported overall incidence of HCC and associated risk factors. At a median 18.4 (IQR 11.9-24.9) years of follow-up, incidence of HCC was 2% (0.01-0.04). Only use of anticoagulation was associated with a lower risk of HCC (RR 0.3, 95% CI 0.1-0.88). DiscussionBy 30 years after Fontan, cumulative incidence of HCC is high (7%). Risk of HCC development prior to 10-years post-Fontan is low (0%) and HCC screening can be safely deferred in this population. Screening with ultrasound every 6 months starting 20-years post-Fontan is reasonable, however, further research regarding timing, cost-effectiveness, additional risk factors associated with HCC risk, and different screening modalities is required.

show abstract

EASL-ERN position paper on liver involvement in patients with Fontan-type circulation

Téllez,

Payancé,

Tjwa

et al. 2023

Journal of Hepatology

View full text Add to dashboard Cite

Hepatic adenoma masquerading as a hepatocellular carcinoma in a patient with a Fontan procedure on the oral contraceptive pill

Cited by 3 publications

References 6 publications

A meta-analysis of cumulative incidence of hepatocellular carcinoma after the Fontan operation

A meta-analysis of cumulative incidence of hepatocellular carcinoma after the Fontan operation

A Meta-Analysis of Cumulative Incidence of Hepatocellular Carcinoma After the Fontan Operation

EASL-ERN position paper on liver involvement in patients with Fontan-type circulation

Contact Info

Product

Resources

About